Additionally, Legumain, a cysteine protease known for its role in promoting ferroptosis by interacting with the ferroptosis inhibitor GPX4, is being investigated as a potential therapeutic target and an early diagnostic marker for IRI-AKI [80]. The gene discussed is GPX4; the disease is acute kidney injury.